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The use of intensity-modulated radiation therapy (IMRT) is rapidly advancing in the field of radiation oncology. Intensity-modulated
radiation therapy allows for improved dose conformality, thereby affording the potential to decrease the spectrum of normal tissue
toxicities associated with IMRT. Preliminary results with IMRT are quite promising; however, the clinical data is relatively immature
and overall patient numbers remain small. High-quality IMRT requires intensive physics support and detailed knowledge of three-
dimensional anatomy and patterns of tumour spread. This review focuses on basic principles, and highlights the clinical
implementation of IMRT in head and neck and prostate cancer.
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Intensity-modulated radiation therapy (IMRT) represents a
promising new advance in the field of radiation oncology.
Intensity-modulated radiation therapy allows for improved ‘shap-
ing’ of radiation dose profiles around tumour and at-risk nodal
structures while sparing adjacent normal tissue structures. This
capacity for improved dose distribution affords considerable
opportunity to reduce the overall toxicity profile associated with
radiation therapy. The use of IMRT is advancing rapidly world-
wide as this technology has become commercially available.
Despite considerable promise, IMRT use remains in relatively
early stages, and must be delivered with strict attention to quality
assurance as the clinical data and patient follow-up mature.
Furthermore, IMRT is quite labour-intensive, with strong depen-
dence on physics and quality assurance support, thus leaving open
the possibility for significant heterogeneity in the precision of
IMRT practice.
What is IMRT?
Intensity-modulated radiation therapy refers to a specific techni-
que of linear accelerator-based radiation therapy whereby beams
are modulated in such a manner to produce highly conformal dose
distributions. A primary objective of IMRT is to reduce dose to
selected normal tissue structures in an effort to preserve function,
while maintaining full dose delivery to tumour targets. For
example, in conventional head and neck (H&N) radiotherapy,
static fields are shaped by blocks and modulated by simple beam
wedges or tissue compensators (Harari et al, 1998). In contrast,
IMRT is delivered by individually modulated fields (step and shoot
or sliding window technique) or by a rotating linear accelerator
gantry (serial or helical tomotherapy). Variable dose intensities
can be delivered through the segments of each treatment field,
thereby maximizing conformality of the ultimate dose distribution.
Intensity-modulated radiation therapy planning is conceptually
distinct from conventional radiotherapy planning. For both
conventional (3D conformal radiation therapy, 3D-CRT) and
IMRT planning, the radiation oncologist designates specific targets
(gross tumour, elective nodal regions) and avoidance structures
(rectal wall, bladder, spinal cord, salivary glands, optic apparatus,
etc.). In 3D-CRT, simple beam arrangements are used with
generous field margins to account for daily set-up variation and
physical characteristics of the beam itself. The radiation dose and
profile is then calculated in a process known as forward planning.
In contrast, IMRT planning requires that the physician define dose
specifications for both the target and avoidance structures. The
computer planning software then creates a series of modulation
patterns at each beam angle that strive to achieve the physician’s
dose prescription goals. This process is known as inverse planning.
Brief history of IMRT
Intensity-modulated radiation therapy was first conceptualised in
the 1960s. However, it was not until the 1980s–1990s that the
computing capability required for complex inverse planning
algorithms became commercially available (Intensity Modulated
Radiation Therapy Collaborative Working Group, 2001). In 1994,
the NOMOS Peacock system was introduced as the first
commercial IMRT delivery unit. The Peacock system required
the use of a beam modulation device known as a dynamic
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www.bjcancer.commultivane intensity-modulating collimator (MIMiC). This parti-
cular form of IMRT is called serial tomotherapy, as ‘slices’ could be
treated by a continually rotating gantry (Intensity Modulated
Radiation Therapy Collaborative Working Group, 2001). Step and
shoot IMRT represents another commonly used technique where-
by multiple static beams are subdivided into ‘segments’. In the
sliding window technique, a window defined by the MLC leaves
sweeps across the treatment field at variable speed, while the
monitor units are delivered continuously (Ling et al, 1996). With
serial and helical tomotherapy, the intensity modulation is
achieved through the use of a binary MLC (radiation is either
delivered or not). In contrast to serial tomotherapy, helical
tomotherapy is characterised by translation of the treatment
couch during treatment delivery, allowing large field lengths to be
treated in a single spiral (Mackie et al, 1999). Moreover, a CT
detector array diametrically opposed to the energy source allows
for image and dose reconstruction capabilities during treatment.
Each of these systems shares commonality of need for intensive
physics support, precise anatomical target definition, and rigorous
quality assurance (Richardson et al, 2003; Fenwick et al, 2004).
CLINICAL IMPLICATIONS
Clinical research efforts in IMRT have generally considered two
basic paradigms. The first research strategy seeks to maintain
current tumour control rates while decreasing toxicity profiles. For
example, IMRT studies in H&N cancer commonly strive to
maintain conventional dose to primary tumour and at-risk nodal
regions, while diminishing dose to adjacent normal tissue
structures such as salivary glands and spinal cord. The second
strategy attempts to escalate tumour target dose while maintaining
acceptable levels of toxicity. This approach has been taken in dose-
escalation and hypofractionation trials for prostate cancer and
more recently in lung cancer. Regardless of the primary objective,
precise, reproducible accurate patient/target set-up and rigorous
physics quality assurance are critical to successful IMRT delivery.
In this review, we highlight the role of IMRT in two of the most
common anatomic sites of current use; H&N and prostate cancer.
Clinical applications in H&N cancer
Radiation plays a central role in the treatment of H&N cancer. New
radiation delivery techniques offer powerful potential to diminish
the spectrum and severity of radiation toxicities for H&N cancer
patients. For many decades, conventional H&N radiation techni-
ques have involved treatment with generous opposed lateral beams
to encompass the known primary tumour and upper cervical
lymphatics. This classical technique produces a relatively homo-
geneous dose distribution that allows excellent target dosing while
minimizing hot and cold spots. However, due to the tight
proximity of tumour targets and normal tissue in the H&N region,
many uninvolved structures including salivary glands, spinal cord,
auditory apparatus, optic apparatus, mandible, and vocal cords
can unnecessarily receive high doses of radiation.
In H&N cancer, one of the most common rationales for IMRT is
to preserve salivary gland function and thereby diminish the
severity of chronic xerostomia with associated adverse impact on
taste, swallowing, dentition, speech, and overall quality of life. In
addition, the capacity of IMRT to limit dose to normal tissue
structures may also allow dose escalation and differential dose
painting, thereby accomplishing ‘in-field tumour boosting’ (Butler
et al, 1999).
Early reports have described clinical promise with H&N IMRT,
both for tumour control and reduction of xerostomia. However,
these data generally represent limited single-institution experience,
often with heterogeneous cohorts of patients (postoperative vs
definitive, chemotherapy vs no chemotherapy, varying dose/
fractionation schemes). Prospective, multiinstitutional protocols
that incorporate IMRT for H&N cancer patients remain in very
early stages.
More mature clinical data regarding the efficacy of IMRT in the
management of H&N cancer is now emerging. Preliminary single-
institution experience with IMRT suggests favourable outcome.
While these results can be interpreted with caution, given the small
overall numbers and careful patient selection, they suggest that
H&N IMRT appears to be safe and effective in appropriately
selected patients.
The Washington University experience with H&N IMRT
included 126 patients (Chao et al, 2003). In total, 41% of patients
were treated definitively and the remainder postoperatively. The 2-
year actuarial locoregional control rate was 85%. Patterns of
recurrence from patients treated at the University of Michigan with
parotid sparing H&N IMRT techniques were recently reported
(Dawson et al, 2000). A total of 58 patients with primary H&N
cancer were treated definitively or postoperatively and followed for
a median of 27 months. A 79% local rate of control was achieved
with 12 patients developing recurrence by 2 years. Investigators at
Baylor reported on 20 patients with primary H&N tumours
showing 19 patients with a complete response to therapy and a
significant reduction of dose to parotid glands (Butler et al, 1999).
With a median follow-up of 13.5 months, two patients who
achieved complete response developed local recurrence at 10 and
15 months. Treatments were generally well tolerated. Lee et al
(2002) reported on 67 patients with nasopharyngeal carcinoma
who were treated with IMRT. Of 58 patients, 50 were treated with
concomitant and adjuvant chemotherapy. With a median follow-
up of 31 months, a local regional progression-free rate of 98% was
observed. A recent update with 118 patients continues to
demonstrate excellent locoregional control rates (Bucci et al,
2004). These results have stimulated further evaluation of H&N
IMRT in an ongoing cooperative group trial for nasopharynx
cancer patients through the Radiation Therapy Oncology Group.
Xerostomia brings significant long-term consequences for the
H&N cancer patient. Lack of salivary production can lead to sore
throat, decreased taste, dental decay, mandibular osteoradione-
crosis, and impaired voice and swallowing functioning. Intensity-
modulated radiation therapy techniques afford distinct opportu-
nities for salivary gland sparing (Figure 1). Investigators at the
University of Michigan suggest that mean doses of p26Gy to the
parotid gland may afford substantial sparing of long-term parotid
gland function. At p26Gy, excellent preservation of salivary
function (unstimulated and stimulated, respectively) was observed
(Eisbruch et al, 1999). This group has also demonstrated that
salivary flow correlates with improved quality of life, suggesting
that parotid sparing may be associated with improved overall
clinical outcome (Eisbruch et al, 2001). Chao et al (2001) have
reported on results of a trial examining the functional outcome of
salivary glands at 6 months following radiation. Mean dose to the
parotid gland was shown to correlate with ultimate salivary flow in
41 patients analysed. More recent studies continue to suggest that
salivary sparing is possible with IMRT using proper technique
(Astreinidou et al, 2004) and may favourably impact overall
quality of life (Reddy et al, 2001; Parliament et al, 2004).
While these studies suggest that IMRT represents a promising
new therapy in H&N cancer, early results must be viewed with
some caution. Aside from the nasopharynx data, these series
include a heterogeneous group of H&N patients, some treated
definitively and some postoperatively. Chemotherapy regimens
and fractionation regimens vary within and across the published
series. Overall follow-up for the patients remains relatively short.
The specific techniques of IMRT treatment show evolution within
each of these updated series. These factors suggest that ongoing
careful and systematic evaluation regarding acute and long-term
outcomes with H&N IMRT should be pursued. Data are emerging
regarding key contributing factors for disease control and
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and treatment technique. Chao et al (2004) identified that primary
tumour GTV and nodal GTV size independently predicted for
therapeutic outcome. Patterns of failure analysis in patients treated
with IMRT led Eisbruch et al (2004) to recommend careful
attention to retropharyngeal nodes in patients with oropharyngeal
primaries. Further reports based on clinical outcome will continue
to shape the practice of H&N IMRT.
Clinical applications in prostate cancer
The past decade has provided new data regarding of the
importance of dose escalation in the treatment of localised
prostate cancer. Pollack et al (2002) reported results of a seminal
phase III study of dose escalation at the MD Anderson Cancer
Center. Patients with low- or intermediate risk localised prostate
cancer were randomised to 70 vs 78Gy. The high dose arm showed
a statistically significant improvement in freedom-from-failure.
These results are further supported by several single-institution
series (Zelefsky et al, 1998a,b; Pollack et al, 2004).
Escalation of radiation dose to the prostate brings increased
toxicity risks, particularly rectal complications. When delivered
with conventionally planned techniques, doses higher than 70Gy
are associated with higher complication rates (Pollack et al, 2002;
Tucker et al, 2004). It has now become clear that 3D conformal
radiotherapy techniques allow improved overall treatment toler-
ance of higher doses (Nguyen et al, 1998; Zelefsky et al, 1998a,b;
Michalski et al, 2000) but complication rates, particularly rectal
bleeding, can remain substantial. Several analyses suggest that the
total volume of rectal wall exposed to greater than 60–70Gy
predicts the rate of grade 2 (rectal bleeding) or more severe
complications. Therefore, the implementation of IMRT, with the
ability to further reduce rectal dose (Figure 2), should further
reduce toxicities, as has recently been reported (Zelefsky et al,
2002).
Increasing the conformality of radiation dose requires increased
set-up precision. In recent years, transabdominal ultrasound
systems have been employed to more accurately target the prostate
on a daily basis (Lattanzi et al, 1999; Lattanzi et al, 2000; D’Amico
et al, 2001). As an alternative, the implantation of small metal
seeds into the prostate to serve as fiduciaries during daily portal
imaging has also proven reliable as a means of reproducibly
localising the prostate (Nederveen et al, 2003). In addition, it has
been demonstrated that the use of a rectal balloon catheter can
immobilise the prostate and facilitate localisation on port films
potentially allowing tighter margins for the treatment volume
(Wachter et al, 2002). Further, the lateral and posterior aspects of
the rectal wall are partially displaced out of the high dose region by
the rectal balloon, which offers the potential for significant rectal
dose sparing (Patel et al, 2003).
A number of centres have sought to reduce the number of
fractions required for prostate cancer treatment by increasing
fraction size. While the rationale has been primarily for logistical
and resource utilisation purposes in the past, it has recently
become better appreciated that prostate cancer may have unique
radiobiological properties (increased ability to repair damage). It
may, therefore, prove advantageous to use larger daily fractions of
42.0Gy (hypofractionation), rather than conventional 1.8–2.0Gy
fractions commonly employed, when treating most other tumour
types. Using linear quadratic formulation, one can predict an
improved ratio of tumour control to normal tissue toxicity (the
therapeutic ratio) for prostate cancer by using hypofractionation
(Fowler et al, 2001). Cleveland Clinic investigators have carried out
a trial of hypofractionation consisting of 28 fractions of 2.5Gy for a
total dose of 70Gy (Kupelian et al, 2002). Intensity modulated
radiotherapy and daily pretreatment ultrasound-based prostate
localisation were employed to improve treatment precision and
reduce radiation dose to the rectum. These early results appear to
indicate disease control (PSA recurrence-free survival) at least
equivalent to that seen with standard fractionation, although
follow-up remains short. Given the smaller number of larger
radiation doses delivered, highly conformal and accurate radiation
techniques like image-guided IMRT afford the opportunity for the
exploration of novel fractionation regimens, which ultimately may
improve local control and cost-effectiveness. However, with the
delivery of fewer treatment fractions, errors incurred through daily
set-up variations or internal organ motion with each fraction will
have a larger impact on overall treatment, and therefore there is
clear need for high precision patient localisation techniques with
such treatment strategies (Keller et al, 2004; Orton and Tome,
2004).
IMRT precautions
As with any new technology, there is enthusiasm mixed with
caution regarding the use of IMRT. Some have voiced concern
regarding the embracement of IMRT as a standard approach until
the completion and comparative evaluation of systematic clinical
trials (Halperin, 2000; Glatstein, 2003). Nevertheless, the global
use of IMRT has increased dramatically over the last several
Figure 1 Isodose distributions contrasting conventional (left) and IMRT (right) H&N treatment plans. Significant reduction of dose to the left parotid gland
is achieved with the IMRT plan.
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by Mell et al (2003), one-third of respondents reported that
they were currently using IMRT. In addition, over 90% of
respondents who were not currently using IMRT stated that
they planned to do so in the near future. Despite increased
utilisation, several notes of caution regarding the use of IMRT
are worthy of mention.
IMRT standardisation There exists a lack of global standardisa-
tion in IMRT planning and delivery. The literature describes
several distinct IMRT techniques, and several aspects of the IMRT
planning processes remain highly practitioner dependent. A
variety of fractionation regimens and target delineation techni-
ques are in common use. In a recent study, substantial variation in
both target delineation and fractionation recommendations were
observed among worldwide H&N experts when provided the
identical tonsil cancer case (Figure 3) (Hong et al, 2004). Subtle
technique distinctions can pose considerable challenge to new
institutions that wish to commence use of IMRT. For these
reasons, it is increasingly important to provide standardised
recommendations and guidelines for IMRT planning. Indeed,
guidelines are beginning to emerge with specific recommenda-
tions for nodal coverage targets based on tumour location and
stage (Eisbruch et al, 2002; Gregoire et al, 2003; Levendag et al,
2004).
IMRT set-up precision Radiation oncologists have been tradi-
tionally trained to use large field margins to cover unsuspected
tumour infiltration and to avoid geographical miss. Since a
major goal of IMRT is to limit dose to normal tissue structures
that often reside very close to tumour targets, daily set-up
precision takes on much greater significance. A recent study
suggests that the daily set-up variations with conventional H&N
masking and immobilisation techniques may be insufficient to
ensure high-quality IMRT delivery over a 6–7 week course of
treatment (Hong et al, 2005). Indeed, daily set-up errors of
several mm can result in underdosing of tumour or overdosing
of normal tissues such as the ‘spared’ parotid gland, under-
scoring the importance of rigorous quality assurance processes
for IMRT.
Radiation exposure Another theoretical concern with IMRT
involves the increased machine output (monitor units) required
for IMRT delivery and the potential for increased radiation
exposure. With increased modulation of the radiation beam, more
monitor units are generated to deliver the prescribed dose.
Consequently, there can be increased leakage from the linear
accelerator, increasing the total body exposure by 2–3 fold (Hall
and Wuu, 2003). In a recent publication, Hall et al suggest that this
increase in total body dose could potentially increase the rate of
second malignancy from 1% per 10 years to 1.75% per 10 years, an
Figure 2 Isodose distributions contrasting conventional 3D conformal (left) and IMRT (right) prostate treatment plans. The arrows highlight improved
conformality to the prostate and seminal vesicles and decreased rectal volume receiving high dose with the IMRT plan.
Figure 3 Variations in H&N target delineation. Highly distinct CTV designs from two H&N experts which illustrate broad variation in target delineation
strategies for the identical tonsil case.
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will be required to determine if IMRT does in fact enhance this
risk.
Future IMRT trials As H&N IMRT steadily advances into more
common use, the design of clinical trials that explore the use of
chemoradiation, altered fractionation, and molecular targeted
therapy becomes more complex. Indeed, the cooperative oncology
groups are struggling currently with systematic methodology to
credential and quality-assure the process of H&N IMRT for
participating institutions. The successful accomplishment of future
H&N cancer treatment trials will need to acknowledge the
increasing use of IMRT despite inherent difficulties in trial design
and quality assurance. This represents a significant challenge in
that a broad series of promising molecular agents, that may
enhance radiation response are becoming available. However, the
profound variation in IMRT expertise and delivery technique
across institutions currently renders this an added variable that
serves to complicate the evaluation of new molecular agents with
radiation.
In prostate cancer, novel hypofractionated regimens have been
proposed to exploit radiobiological properties with significant
shortening of treatment time without loss of efficacy or increase in
toxicity (Fowler et al, 2003). Indeed, investigators are exploring the
utility of IMRT in a number of other clinical scenarios, including
brain tumours, lung cancer, upper GI malignancies, breast cancer,
gynaecologic malignancies, and many other sites. The primary
objectives focus on reduction of toxicity and/or increased dose to
the tumour target.
Other new aspects of IMRT research include the integration of
sophisticated image-guidance. As discussed previously, the steep
dose gradients created by IMRT plans can increase the risk of
geographical target miss or unintentional overdosing of spared
structures. Recent technologies such as ultrasound position
verification, cone beam CT, and MVCT with helical tomotherapy
offer methods to ‘visualise’ daily treatment set-up and reduce set-
up variability and resultant dosimetric uncertainty (Mackie et al,
2003). Indeed, high-quality IMRT is highly dependent on accurate
and reproducible patient set-up.
Future directions and conclusions
There is no question that the use of IMRT in modern cancer
therapy is expanding worldwide. This promising technology
advancement brings clear opportunity to improve the therapeutic
ratio for cancer patient outcome. The early clinical reports to date
are quite promising for several distinct tumour types. However,
improved definition of those specific parameters (tumour and
normal tissue) that render patients most likely to truly benefit from
IMRT will be valuable. The time, expense, and expertise required to
realise optimised and reproducible IMRT delivery across institu-
tions warrants acknowledgement regarding the most appropriate
usage and necessary quality assurance processes to ensure patient
benefit and safety. The systematic accumulation of clinical data is
of great importance for advancement in this field. Ideally, this data
will come in the form of controlled clinical trials that rigorously
examine not just radiation physics and dosimetry, but acute and
late normal tissue effects with long term clinical follow up.
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